2028年までの中南米心血管代謝疾患市場予測 - 新型コロナウイルス感染症の影響と地域分析（心血管疾患（CVD）、2型糖尿病、高血圧、肥満）、治療法（ACE阻害剤、利尿剤、グルコファージなど）、用量（錠剤、注射）、投与経路（経口、静脈内）、エンドユーザー（病院、診療所、在宅医療環境）、流通チャネル（病院の薬局、小売薬局、オンライン薬局）
市場紹介
心臓代謝疾患は、以下のような一連の異常と症状を特徴としています。個人が心血管疾患を発症するリスク。高血圧、肥満、インスリン抵抗性、脂質異常症、コレステロールプロファイル（LDL）低下、耐糖能などが症状の一部です。心メタボリックシンドロームに罹患している人は、2 型糖尿病、脳卒中、冠動脈疾患 (CAD)、心血管疾患 (CVD) など、他のいくつかの生命を脅かす病気にかかりやすいです。
さらに、心臓代謝性疾患の有病率の増加により、予測期間中の市場の成長が促進されると予想されます。しかし、低中所得国 (LMIC) における CVD の過小診断により、中南米の心臓代謝疾患市場の成長が制限されています。
ブラジル、アルゼンチン、ウルグアイ、チリ, ペルー、コロンビアはコロナ感染第2波が懸念されている。このうちブラジルが死者の大多数を記録している。この地域ではおそらく二度目のロックダウンが強制される可能性が高く、最終的にはこの地域の医療産業に支障をきたすことになると予想されている。この新型コロナウイルス感染症のパンデミックの最中に、SARS-CoV-2感染を予防し治療するための薬物療法を探求する集中的な試みが行われてきた。したがって、この地域における新型コロナウイルスの心臓代謝疾患市場に関する進行中の臨床研究は、市場の成長を促進する可能性があります。
>市場の概要とダイナミクス
中南米の心臓代謝疾患市場は、米国から2028年までに102億9,550万米ドルに達すると予測されています。 2021年には84億7,260万ドル。 2021 年から 2028 年までに 2.8% の CAGR で成長すると予想されています。医療業界の画一的なアプローチからターゲットを絞ったアプローチへの変革により、個別化医療の需要が拡大しています。個人の遺伝子構造に基づいた個別化医療の進歩により、これらの医薬品は着実に慢性疾患治療のトレードマークになりつつあります。慢性疾患に対する個別化された治療の統合に関する研究が増加しており、新たな治療の道が開かれています。大手製薬会社もCMDに対する個別化された治療法の選択肢を模索している。最近、ノバルティスは Akcea Therapeutics から、心臓血管標的療法の治験薬である TQJ230 を開発および商品化する権利を取得しました。何百万人もの人々が、食事やその他のライフスタイルの変更によって効果的に対処できない、独立した遺伝性の CVD 危険因子であるリポタンパク質 (a) を上昇させています。 TQJ230 が承認されれば、Lp(a) の上昇を明確に標的とするファーストインクラスの治療法となる可能性があります。また、AI とデータ分析の進歩により、医薬品を個別化して正確な介入を提供することで疾患管理の発展が支援されています。これらの要因により、中南米の心臓代謝疾患市場の成長軌道が加速しました。
主要市場セグメント
種類の観点から見ると、2020 年には心血管疾患セグメントが中南米心血管代謝疾患市場で最大のシェアを占めました。治療に関しては、ACE 阻害剤セグメントが最大のシェアを占めました。 2020年の中南米心血管代謝疾患市場で最大のシェアを占めた。用量の点では、2020年の中南米心代謝疾患市場で錠剤セグメントが最大のシェアを占めた。投与経路の点では、経口セグメントが占めた。エンドユーザーの観点からは、2020年に中南米の心臓代謝疾患市場で最大のシェアを占めたのは病院セグメントでした。さらに、流通チャネルに基づいて、病院薬局部門 は、2020 年に最大の市場シェアを保持しました。
上場されている主要な供給源と企業 >
南米および中米の心臓代謝疾患市場に関するこのレポートを作成するために参照したいくつかの主要な一次および二次情報源は、企業の Web サイト、年次報告書、財務報告書、政府機関です。文書、統計データベースなど。このレポートに記載されている主要企業は、バイエル AG、ノバルティス AG、興和株式会社、ベーリンガー インゲルハイム インターナショナル Gmbh、ノボ ノルディスク A/S、アストラゼネカです。
レポートを購入する理由
- 南部を理解するため中米心血管代謝疾患市場の状況を把握し、高い収益を保証できる市場セグメントを特定する
- 絶えず変化する市場状況を理解し、競争で優位に立つため
- 最も売上が見込まれるセグメントを特定することにより、中南米の心臓代謝疾患市場における合併・買収およびパートナーシップ取引を効率的に計画するため
- < span>さまざまなセグメントの市場パフォーマンスの知覚的かつ包括的な分析から知識に基づいたビジネス上の意思決定を行う
- 中南米の心臓代謝疾患市場の市場収益予測を取得する2021 ～ 2028 年のさまざまなセグメントに基づく
南米および中米心血管代謝疾患市場セグメンテーション >
タイプ別
- 心血管疾患 (CVD)
- 2 型糖尿病
- 高血圧
- 肥満
治療別
- ACE阻害剤
- 利尿薬
- グルコファージ
- その他
< scan>用量別
- 錠剤
- 注射
投与経路別
- 経口
- 静脈内
エンドユーザーによる
- < span>病院
- クリニック
- 在宅医療の設定
< scan>流通チャネル別
- 病院薬局
- 小売薬局
- オンライン薬局
国別
- 中南米
- ブラジル
- アルゼンチン
- 中南米のその他の地域
記載されている企業
- バイエル AG
- ノバルティス AG ;
- ベーリンガー インゲルハイム インターナショナル Gmbh
- ノボ ノルディスク A/S
- アストラゼネカ
- 興和株式会社
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 South and Central America Cardiometabolic Diseases market – By Country
2. South and Central America Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South and Central America Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. South and Central America Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. South and Central America Cardiometabolic Diseases Market – Regional Analysis
6.1 South and Central America Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. South and Central America Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. South and Central America Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. South and Central America Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. South and Central America Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. South and Central America Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. South and Central America Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. South and Central America Cardiometabolic Diseases Market – Geographic Analysis
13.1 South and Central America: Cardiometabolic Diseases Market
13.1.1 Overview
13.1.2 South and Central America: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.3 South and Central America: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.4 South and Central America: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.5 South and Central America: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.6 South and Central America: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.7 South and Central America: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.8 South and Central America: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.9 South and Central America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.1.9.1 Brazil: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.1 Brazil: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.10 Brazil: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.11 Brazil: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.12 Brazil: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.13 Brazil: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.14 Brazil: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.15 Brazil: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.15.1 Argentina: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.15.1.1 Argentina: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.16 Argentina: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.17 Argentina: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.18 Argentina: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.19 Argentina: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.20 Argentina: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.21 Argentina: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.21.1 Rest of South and Central America: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.21.1.1 Rest of South and Central America: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.22 Rest of South and Central America: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.23 Rest of South and Central America: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.24 Rest of South and Central America: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.25 Rest of South and Central America: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.26 Rest of South and Central America: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.27 Rest of South and Central America: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on South and Central America Cardiometabolic Diseases Market
14.1 South and Central America: Impact Assessment of COVID-19 Pandemic
15. South and Central America Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Bayer AG
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Novartis AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Boehringer Ingelheim International GmbH
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Novo Nordisk A/S
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 AstraZeneca
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 Kowa Company, Ltd.
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. South and Central America Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. South and Central America Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 3. South and Central America Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 4. South and Central America Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 5. South and Central America Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 6. South and Central America Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 7. Brazil Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Brazil Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 9. Brazil Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 10. Brazil Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 11. Brazil Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 12. Brazil Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 13. Argentina Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 14. Argentina Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 15. Argentina Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. Argentina Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 17. Argentina Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 18. Argentina Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 19. Rest of South and Central America Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 20. Rest of South and Central America Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 21. Rest of South and Central America Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. Rest of South and Central America Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 23. Rest of South and Central America Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 24. Rest of South and Central America Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 25. Organic Developments in the Cardiometabolic Diseases Market
Table 26. Inorganic Developments in the Cardiometabolic Diseases Market
Table 27. Glossary of Terms, South and Central America Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. South and Central America Cardiometabolic Diseases Market Segmentation
Figure 2. South and Central America Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of South and Central America Cardiometabolic Diseases Market
Figure 4. South and Central America Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. South and Central America Cardiometabolic Diseases Market, Industry Landscape
Figure 6. South and Central America PEST Analysis
Figure 7. South and Central America Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. South and Central America Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. South and Central America: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million)
Figure 34. South and Central America Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million)
Figure 35. South and Central America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 36. Brazil: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 37. Argentina: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 38. Rest of South and Central America: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 39. Impact of COVID-19 Pandemic on South and Central America Cardiometabolic Diseases Market
Figure 40. Growth Strategies in the Cardiometabolic Diseases Market (%)
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Kowa Company, Ltd.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South and Central America cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the South and Central America cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.